Literature DB >> 7906196

Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.

S Marsigliante1, A Muscella, V Ciardo, S Barker, G Leo, V Baker, A Mottaghi, G P Vinson, C Storelli.   

Abstract

One hundred and nine primary breast cancers were analyzed to assess the presence of the HER-2/neu gene product (p185), the oestrogen (ER) and the progesterone (PR) receptors, and the total cathepsin D status. An enzyme-linked immunosorbent assay (ELISA kit, Oncogene Science Inc.) was used for the evaluation of p185 in pellets obtained after a 100,000 x g centrifugation, ER and PR were measured by enzyme immunoassay (EIA kit, Abbott Laboratories), and the total cathepsin D content was evaluated by immunoradiometric assay (IRMA kit, CIS Biointernational). We showed that the ELISA kit is feasible to quantify the p185 present in breast cancer cell membranes, and that the detector antibody recognises a protein of apprroximatly M(r) 185,000. The detected antigen was inversely related to both ER and PR, but it did not correlate to total cathepsin D. No significant differences were found in the expression of p185, ER, PR, cathepsin D between infiltrating ductal carcinomas without special features (NOS) and non-ductal (non-NOS) carcinomas. Nevertheless, in NOS carcinomas, a trend was observed in the p185 levels expressed by the tumours with different histological grades, in that p185 concentration was higher in the poorly differentiated grade 3 with respect to grade 2 and grade 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906196     DOI: 10.1016/0304-3835(93)90062-e

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

Review 1.  Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

Authors:  I Vaz-Luis; E P Winer; N U Lin
Journal:  Ann Oncol       Date:  2012-09-28       Impact factor: 32.976

2.  Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Authors:  H J Huang; P Neven; M Drijkoningen; R Paridaens; H Wildiers; E Van Limbergen; P Berteloot; F Amant; I Vergote; M R Christiaens
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

3.  Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Authors:  Maria D Corte; Juan A Rodil; Julio Vázquez; Lucia García; Juan C Rodríguez; Miguel Bongera; José C Fernández; Luis O González; Ma Luz Lamelas; Maite Allende; José L García-Muñiz; Antonio Fueyo; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

4.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

5.  Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.

Authors:  W F Anderson; S Luo; N Chatterjee; P S Rosenberg; R K Matsuno; M T Goodman; B Y Hernandez; M Reichman; M P Dolled-Filhart; R M O'Regan; M Garcia-Closas; C M Perou; I Jatoi; R W Cartun; M E Sherman
Journal:  Breast Cancer Res Treat       Date:  2008-02-07       Impact factor: 4.872

6.  A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.

Authors:  Qianqian Guo; Kai Chen; Xiaojie Lin; Yi Su; Rui Xu; Yan Dai; Chang Qiu; Xue Song; Siying Mao; Qianjun Chen
Journal:  Oncotarget       Date:  2017-07-17

Review 7.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.